CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of

Planned U.S. commercial launch of ZULRESSO™ (brexanolone) injection, if approved, on track for June 2019 , based on PDUFA target date of March 19, 2019 and anticipated DEA scheduling Topline data from Phase 3 trial of SAGE-217 in MDD expected in Q4 2019 or 1Q 2020 Neurology and neuropsychiatry

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2019-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2019 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2019-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski ,

– Multi-franchise strategy ongoing in depression, neurology and neuropsychiatry – – Commercial infrastructure build completed for ZULRESSO™ (brexanolone) injection ahead of March 19, 2019 target PDUFA date – – Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum

– Statistically significant reduction observed in depressive symptoms compared to placebo in women with postpartum depression (PPD) – – Well-tolerated with rapid onset of statistically significant effect (Day 3) through two weeks and maintained for four weeks after treatment – CAMBRIDGE, Mass.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2019-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 27, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the J.P.